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Abstract
We have developed an efﬁcient, streamlined, cost-effective approach to obtain Investigational New
Drug (IND) approvals from the Food andDrug Administration (FDA) for positron emission tomography
(PET) imaging probes (while the FDA uses the terminology PET drugs, we are using “PET imaging
probes,” “PET probes,” or “probes” as the descriptive terms). The required application and supporting
data for the INDs were collected in a collaborative effort involving appropriate scientiﬁc disciplines.
This path to INDswas successfully used to translate three [18F]ﬂuoro-arabinofuranosylcytosine (FAC)
analog PET probes to phase 1 clinical trials. In doing this, a mechanism has been established to fulﬁll
the FDA regulatory requirements for translating promising PET imaging probes from preclinical
research into human clinical trials in an efﬁcient and cost-effective manner.
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Introduction
positron emission tomography (PET) is an exceptionallysensitive and noninvasive imaging modality that pro-
duces a quantitative, three-dimensional image of biological
and pharmacological processes occurring in the body. This
study’s approach involves administration of PET imaging
probes and detection of the resulting 511-MeV gamma rays,
due to positron decay, with a PET scanner. Over the past
three decades, more than 2,000 PET probes have been
developed [1] to provide assays of a wide array of biological
and pharmacological processes. Based on the data available
from the National Institutes of Health, Molecular Imaging
and Contrast Agent Database, 1,361 PET probes have been
utilized in animal studies and only 118 of these PET probes
to date have been used in human studies. This rather low-
percentage transition of probes to investigations in humans
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can be attributed to (1) nonoptimal bio-distribution and in
vivo targeting of probes in animal models, understanding
that there are limitations in the translation of animal bio-
distribution data to humans, and (2) the difﬁculties and costs
associated with gathering data and ﬁling appropriate appli-
cations for Food and Drug Administration (FDA) approval
to initiate these studies in humans. Thus, it is reasonable to
surmise that there is a critical but unmet need to identify an
efﬁcient and cost-effective methodology of translating
promising PET probes from the preclinical to the clinical
domain and obtaining ﬁrst-in-human data.
Approval for administration of the PET probes to human
subjects is regulated by the FDA [2]. As directed by Section
121 (c)(1)(A) Modernization Act of 1997, the FDA has
developed speciﬁc current good manufacturing practice
(cGMP) requirements for manufacturing, quality control
testing, and application submission for the approval of PET
probes for human use [3–5]. Currently, there are several
paths available for research use of PET imaging probes in
human subjects (Fig. 1 and Table 1):
1. Radioactive Drug Research Committee (RDRC) is an
FDA-sanctioned institutional committee, deﬁned in the
Code of Federal Regulations (CFR), Volume 21, Part
361.1 [6–8], that provides a review and approval
mechanism for investigators interested in conducting
basic human subject research with PET imaging probes.
These clinical studies are limited to 30 human subjects,
with no diagnostic intent as part of a phase 0 trial.
Typically, limited preclinical data is required for the
approval of RDRC applications, and, as a result, the cost
of obtaining approval for conducting these basic research
studies under RDRC is relatively low. The following
conditions are required for RDRC approval:
(a) The investigation is considered basic science research
and is for the purpose of advancing scientiﬁc knowledge, (b)
the study is approved by an FDA-sanctioned local RDRC,
(c) the pharmacologic dose of the probe to be administered
is known not to cause any detectable pharmacological
effects in humans, and (d) the radiation dose is justiﬁed by
the quality of the study such that the total amount of
radiation to the human subject must be the smallest dose
practical to perform the study without compromising the
beneﬁts of the study.
2. Exploratory Investigational New Drug (eIND)
Application [9] provides an opportunity to conduct ﬁrst-
in-human phase 0 studies of PET imaging probes
involving a limited human pharmacological dose, deﬁned
as equal to or less than 100 μg for imaging agents and
30 nmol for protein products, with no diagnostic intent.
The eIND approach permits lower-cost human imaging
studies through reduced requirements for preclinical
animal testing compared to the traditional IND approach.
The eIND also serves as a useful screening approach by
allowing the sponsor to evaluate two to ﬁve PET probes
simultaneously under one application and select the top
candidate for further clinical development. After eIND
studies are completed, the eIND must be withdrawn and
Fig. 1. FDA approval process for PET imaging probes. Following the preclinical R&D discovery phase, PET probes enter the
phases of clinical development through the IND application pathway. In addition to the IND pathway, when specific criteria are
met, PET probes can be introduced into human subjects as part of the early clinic phase (phase 0) using the RDRC or eIND
mechanisms. It is important to note the RDRC mechanism is not appropriate for first-in-human PET studies, and the detailed
requirements for use of the RDRC mechanism are discussed in the text. An IND application is ultimately required for clinical
development of the PET probe past phase 0. FDA reviews the sufficiency of human safety and efficacy data obtained during the
phases of clinical development, and an NDA application is submitted by the sponsor to seek marketing approval. The PET
probe is considered approved once the FDA completes the review and pre-approval inspection of the manufacturing site and
considers the application submitted satisfactory for approval.
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further studies with the imaging probe are to be conducted
under a traditional IND. This screening approach was
utilized successfully as part of the regulatory process for
AMYvID [10].
If a PET probe study does not qualify for approval through
the RDRC or eIND mechanisms, or IND exemption, which
allows the investigator to conduct a study without submitting
an IND if speciﬁc criteria are met, the IND approach is the only
viable option for introducing the PET probe into human
subjects. An IND exemption applies when a lawfully marketed
PET probe investigation (a) is not intended to support FDA
approval of a new indication, labeling change, or advertising
change; (b) does not involve a change in route of administra-
tion, dosage level, or use in a patient population or other factors
that signiﬁcantly increase the risk to subjects; (c) is conducted
in compliance with the Institutional Review Board (IRB),
deﬁned in 21 CFR Part 56, informed consent, deﬁned in 21
CFR Part 50 [11], and promotion of investigational drugs,
deﬁned in 21 CFR 312.7 [12].
3. INDApplication, deﬁned in 21 CFR Part 312 [13, 14], is the
mechanism for introducing promising investigational PET
probes into phase 1 clinical trials and further clinical
development in phases 2 and 3 for obtaining efﬁcacy and
additional human safety data in support of a New Drug
Application (NDA) approval. The FDA IND guidelines
require Good Laboratory Practice (GLP) compliant [15]
preclinical data including safety pharmacology and toxicol-
ogy studies in two species, one in rodent and one in
nonrodent. In addition, rodent dosimetry data is required in
support of the IND application. The amount of preclinical
safety and toxicology studies for PET probes administered
in trace mass doses, which are generally considered to be
below pharmacologic doses and many orders of magnitude
below toxic effects, are evaluated on a case-by-case basis
and can be reduced, if deemed appropriate, by the FDA
during the pre-IND meetings.
Approach
In the past decades, the UCLA Department of Molecular and
Medical Pharmacology (DMMP) and its Ahmanson
Translational Imaging Division that contains the Nuclear
Medicine and PET/CT research and clinical service have
utilized and continue to utilize the local RDRC approval
mechanism for basic human research on PET probes.
Although RDRC will continue to be a path for academic
scientists to obtain valuable human bio-distribution data for
the purpose of basic research, ﬁrst-in-human studies cannot
be conducted under RDRC. In addition, the FDA
Modernization Act requires investigational use of a PET
probe to be conducted under an IND, unless IND exemption
is granted. To satisfy these requirements and transition
promising PET probe candidates from the preclinical stage
to clinical research, in compliance with the FDA
Modernization Act, we have recently developed an econom-
ical and streamlined method to obtain INDs. This approach
has been possible through a collaborative effort among
several professional groups at UCLA to obtain data and
establish protocols that meet the following critical compo-
nents of IND applications (Fig. 2):
(a) Preclinical toxicology and safety pharmacology studies
are performed by the UCLA Division of Laboratory
Animal Medicine (DLAM). This testing facility is
maintained under GLP [15] and through a collaborative
effort with the Rodent Physiology Core in the Department
of Physiology at UCLA.
(b) Preclinical bio-distribution and dosimetry studies are
conducted by the UCLA Crump Institute for Molecular
Table 1. Comparison of RDRC, eIND, and IND approaches for PET probes
RDRC eIND IND
Purpose - Only for basic research, where the
pharmacologic dose of the drug to be
administered is known not to cause any
detectable pharmacologic effect in
humans
- Only for basic research - For clinical investigation of radiolabeled
probes- Can be used to screen 2–5
probes simultaneously - For therapeutic, diagnostic and
preventative use- For micro-dose studies
- For determining safety and efﬁcacy- When completed, must withdraw and
transition to an IND- Not intended for diagnostic/therapeutic
- Not intended for diagnostic or therapeutic
Requirements - Clinical protocol - Clinical protocol - Clinical protocol
- Manufacturing under USP 823 or
CFR 212 guidelines
- Manufacturing under USP 823 or CFR
212 guidelines
- Manufacturing under USP 823 or CFR
212 guidelines
- Dosimetry studies in rodents - Dosimetry studies in rodents - Dosimetry studies in rodents
- Limited safety/tox studies in rodents
(determined by institutional RDRC)
- Toxicology studies in 1 species - Toxicology studies in 2 speciesa
- No safety pharmacology studies - Safety pharmacology in 2 speciesa
- No genotoxicity studies - Genotoxicity studiesa
Approval Approval by RDRC and IRB Approval by FDA and IRB Approval by FDA and IRB
Subject # Up to 30 Up to 30 No limit
The purpose, requirements, approval process, and subject numbers for the three application paths available to PET probes are provided in this table
aThe amount and type of preclinical safety and toxicology studies required to support a PET probe IND are evaluated on a case-by-case basis and can be
reduced, if deemed appropriate, by the FDA
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Imaging of DMMP. These studies evaluate the bio-
distribution of each probe in three mice and calculate
dosimetry in each organ using the FDA-approved
OLINDA software [16]. In addition to the discovery
and technology inventions for in vitro and in vivo
preclinical molecular imaging diagnostics, the Crump
Preclinical Imaging Technology Center facilitates in vivo
preclinical imaging studies for faculty, students, and
their collaborators.
(c) Chemistry, Manufacturing, and Controls (CMC) are
developed and performed by the Biomedical Cyclotron
facility in the Ahmanson Translational Imaging Division
of DMMP compliant with cGMP requirements (CFR
212 compliant for approved PET probes and USP
Chapter G8239compliant for investigational PET
probes). The Biomedical Cyclotron is involved in the
development and production of PET probes for research
and clinical service within the UCLA David Geffen
School of Medicine and health system, as well as
conducting research to develop new radiolabelling
techniques, probes, and radiosynthesis platforms.
(d) Clinical protocols and clinical studies are developed and
conducted by the UCLA PET/CT facilities in the
Ahmanson Translational Imaging Division of DMMP.
(e) The IND submission strategy was developed through
collaboration with our consultant at Perceptive Informatics/
PAREXEL.
This collaborative approach has been successfully used to
obtain three INDs for the [18F]ﬂuoro-arabinofuranosylcytosine
(FAC) analogs within a 1-year time span, as described below.
FAC Background
Deoxycytidine kinase (dCK) [17] is a rate-limiting enzyme
in the deoxyribonucleoside salvage pathway which is
expressed predominantly in rapidly proliferating cells,
including hematopoietic progenitors in thymus and bone
marrow, activated lymphocytes, and cancer cells [18].
dCK is therapeutically important because it phosphory-
lates the 5′-hydroxyl group in a broad range of
nucleoside analog pro-drugs, such as gemcitabine, thus
converting them to their corresponding pharmacologically
active form. FAC analogs, which include 1-(2′-deoxy-2′-
[18F] ﬂuoro-β-D-arabinofuranosyl)cytosine (D-[18F] FAC),
1-(2′-deoxy-2′-[18F] ﬂuoro-β-L-arabinofuranosyl)cytosine
(L-[18F] FAC), and 1-(2′-deoxy-2′-[18F] ﬂuoro-β-L-
arabinofuranosyl)-5-methylcytosine (L-[18F] FMAC), have
been designed to closely resemble the structure of the
natural dCK substrate, deoxycytidine, and the nucleoside
pro-drug gemcitabine [17, 19]. These probes are transported
into tissue by the same facilitated transport system used by
deoxycytidine and gemcitabine and are competitively phos-
phorylated by dCK (Fig. 3).
In vivo experiments in mice [20] provide evidence that FAC
probes accumulate in tissues proportional to the level of dCK
activity due to phosphorylation by the enzyme. As a result, the
probe accumulation as measured by PET provides the means to
assay the dCK enzyme activity in vivo, analogous to the use of
2-deoxy-2-[18F]ﬂuoro-D-glucose (FDG) for assay of transport
and phosphorylation of glucose [21].
FAC IND
We utilized the IND approach for investigating the three
FAC analogs in human subjects to (a) assess the safety
proﬁle of the FAC probes in human subjects and (b)
determine the bio-distribution of the three FAC analogs in
cancer patients and evaluate whether the in vivo assay of
dCK enzyme activity with PET in cancer patients correlated
with the in vitro assays of dCK expression and enzyme
activity from surgically excised cancer tissues.
Fig. 2. PET probe IND application components. Chemistry, Manufacturing, and Controls (CMC) procedures and data,
preclinical safety pharmacology and toxicology data, dosimetry data, and a clinical protocol are required to be submitted to the
FDA as components of a PET probe IND application. At UCLA, the data and protocols in support of these components have
been obtained from the Biomedical Cyclotron Facility, DLAM, Rodent Physiology Core, Crump Institute for Molecular Imaging
and the Ahmanson Translational Imaging Division in DMMP that contains the Nuclear Medicine clinic.
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To support the submission of IND applications for D-[18F]
FAC, L-[18F] FAC, and L-[18F] FMAC, a 14-day preclinical
safety pharmacology and toxicology study was conducted in
Sprague-Dawley rats by UCLA DLAM and the Rodent
Physiology Core under GLP conditions (Fig. 4). UCLA
maintains AAALAC-accredited animal facilities, and all work
was conducted under authorization by the UCLA Animal
Research Committee (IACUC equivalent). DLAM had previ-
ously conducted a similar study, which resulted in an active
IND for [18F]-FHBG, a PET reporter probe for imaging herpes
simplex virus type 1 thymidine kinase [22]. Sprague-Dawley
rats were selected as the rodent test system for our study to
accommodate the need for multiple blood draws and ease of
direct blood pressure measurement. The rats were randomly
assigned to eight groups of eight (four male and four female
rats in each group) to determine the safety pharmacology and
toxicity effects upon a single, intravenous administration of
nonradioactive forms of each FAC analog in rats. The mass
Fig. 3. FAC PET probe analogs and gemcitabine. The FAC tracer dose used in PET studies is 2.4×10−5–2.4×10−7 times the
therapeutic dose of gemcitabine [23]. FAC and gemcitabine follow the same transport and biochemical pathway in normal and
cancer cells and are activated through phosphorylation by the enzyme dCK. Reprinted with permission of Springer [24].
Fig. 4. Preclinical study overview for FAC. Sprague-Dawley rats were randomly assigned to eight groups of eight (four male
and four female rats in each group) to determine the safety pharmacology and toxicity effects upon an intravenous
administration of nonradioactive form of each of the FAC family of probes in rats. The rats were monitored prior to the
administration of the test substance and up to 14 days following the administration of the test substance (carrier solution or
FAC). The early effects of the administered agents were monitored on day (+1) post injection in groups 1–4, and the late effects
were monitored on day (+14) post injection in groups 5–8. Rats in groups 1 and 5 were administered with the carrier solution
control and those in groups 2/6, groups 3/7, and groups 4/8 were administered with D-[19F]-FAC, L-[19F]-FAC, and L-[19F]-
FMAC, respectively. Administration occurred on day 0.
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dose of each FAC agent used for these toxicity studies was
in excess of 100× the maximum estimated mass dose of
the FAC tracer that would be injected into a human
subject, equivalent to 27.5 μg/kg. The control groups
received only the carrier solution.
In this study, the safety pharmacology and toxicology data, in
addition to daily clinical observations for overall health, were
obtained upon administering each FAC probe to rats. Safety
pharmacology, deﬁned as studies that investigate the potential
undesirable pharmacodynamic effects of a compound on
physiological functions, was evaluated by measurement of body
weight, rectal temperature, heart rate and rhythm, blood pressure,
pulse oximetry, and respiration rate. Toxicology studies, which
assess the toxicity of a compound to an organism in early and
late time points, were evaluated by measuring complete blood
counts, clinical/blood chemistry, necropsy, and histopathology.
The early effects of the administered agents were
monitored on day (+1) postinjection in groups 1–4, and the
late effects of the administered probes were monitored on
day (+14) post injection in groups 5–8. Rats in groups 1 and
5 were administered the carrier solution as the control group
and those in groups 2 and 6, groups 3 and 7, and groups 4
and 8 were administered with the test probes D-[19F] FAC,
L-[19F] FAC, and L-[19F] FMAC, respectively. The preclin-
ical safety pharmacology and toxicology results from these
studies are provided in the supplemental section of this
article. Overall, the results of these safety pharmacology and
toxicology studies with D-[19F] FAC, L-[19F] FAC, and L-[19F]
FMAC performed at 100× of equivalent human dose provide
evidence that these PET probes are safe for administration into
human subjects.
Following completion of preclinical studies for the FAC
analogs, a pre-IND meeting was scheduled with the FDA to
discuss the best approach for submission of the three INDs, one
for each FAC probe. Based on the data package submitted and
guidance on preclinical studies required to satisfy microdose
administration criteria [9], the FDA considered these studies
sufﬁcient and granted a waiver for additional genotoxicity, safety
pharmacology, and toxicology studies in a second nonrodent
species for the initial phase of the clinical studies. It is important
to note that preclinical data requirements and waivers satisfying
Table 2. Cost of obtaining INDs for three FAC PET probe analogs
Performed by Studies Cost
UCLA DLAM Toxicology and safety
pharmacology studies for





Crump Institute for Molecular
Imaging- DMMP, UCLA





IND strategy and guidance $10,000
Total cost $140,000
The cost for obtaining data in support of IND applications for each of the
FAC analogs, D-[18F]-FAC, L-[18F]-FAC, and L-[18F]-FMAC, using
UCLA in-house resources, is $140,000. As a result, the cost for each
application is calculated to be approximately $50,000
Fig. 5. IND submission timeline for PET probes. Based on the UCLA experience, an optimized timeline for generating the data
and obtaining a PET probe IND from the FDA is expected to be 7 months. The pre-IND meeting package preparation followed
by the pre-IND meeting with the FDA can be completed in 3 months. The pre-IND meeting is not required; however, the
meeting is of great value to the sponsor and will allow the FDA and the sponsor to reach an agreement on the types of studies
required to support the IND application. The sponsor can conduct the preclinical safety and toxicology studies after the pre-IND
meeting parallel to completing the remaining components of the IND application. Completion of the preclinical studies and
analysis of the data is expected to last three additional months. At this point, the sponsor will submit the complete IND package
to the FDA and the application, if deemed acceptable by the FDA, will become active after 30 days of review.
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an IND application may vary from one probe to the next and are
determined by the FDA on a case-by-case basis.
INDs, in traditional 11-part paper format, per regulations
in 21 CFR 312.23, were submitted to the FDA for each FAC
analog (D-[18F] FAC, L-[18F] FAC, and L-[18F] FMAC).
Upon completion of the 30-day reviews which responded to
questions raised by the FDA, UCLA was granted permission
to proceed with the phase 1 clinical studies of 20–30 human
subjects for each probe.
Cost
The costs incurred by our department to obtain data in
support of the three FAC INDs totaled $140 K or less than
$50 K/imaging probe (Table 2). Two factors inﬂuenced the
reduced cost for these INDs: (1) the combined safety
pharmacology and toxicology assessment was conducted
for all three PET probes, which resulted in signiﬁcant
savings by allowing one vehicle control group to be used
for all three test groups, and (2) the studies were done in-
house using UCLA facilities on a nonproﬁt fee-for-service
basis. The cost of outsourcing a similar safety pharmacolo-
gy, toxicology, and dosimetry was obtained from two PET
contract research organizations and estimated at $150 K for
one test probe with a vehicle control.
In addition to conducting these studies in an economical
manner, the team at UCLA was successful at obtaining the
IND for L-[18F] FMAC within 6 months of initiating the
preclinical studies in support of the applications. D-[18F]
FAC and L-[18F] FAC IND applications were submitted
subsequently, and the INDs became active within 2 and
7 months of the L-[18F] FMAC IND.
Discussion and Conclusion
The DMMP at UCLA has utilized in-house resources in its
academic setting to establish and implement a path for
satisfying FDA regulatory requirements for approval of PET
probe INDs in a streamlined and reduced cost approach.
This approach has been validated by expeditiously obtaining
the FDA phase 1 approval for three PET imaging probes and
was made successful through concerted efforts of profes-
sionals in the following critical areas: (1) preclinical safety
pharmacology and toxicology; (2) preclinical imaging and
dosimetry; (3) chemistry, controls, and manufacturing; (4)
clinical study design; and (5) an overall IND submission
strategy to satisfy the phase 1 IND requirements in an open and
cooperative manner with the FDA. Using the FAC analog PET
probes developed at UCLA as a case study, we have
demonstrated that this overall phase 1 IND approach can
successfully be applied to obtain FDA approval of phase 1
INDs in an academic site efﬁciently and at a reasonable cost.
Although the protocol developed herein has proved
successful, we recommend requesting a pre-IND meeting
with the FDA prior to initiating preclinical safety pharma-
cology and toxicology studies in rodents. We surmise that if
we had engaged the FDA team earlier and made this request
prior to initiating these studies, safety pharmacology studies
may have been waived or a limited number of studies would
have satisﬁed the FDA, due to the microdose, tracer levels of
PET probes administered according to the eIND guidance
document. As such, it is prudent to initiate a pre-IND FDA
meeting early in the study development process, which may
result in additional cost and time savings for the IND
submission. Based on experience gained from the FAC IND
project, an optimized project timeline to IND for PET probes
is provided here (Fig. 5).
It is the goal of the DMMP at UCLA to continue working
closely with the FDA to fulﬁll the regulatory requirements
for PET imaging probes. New requirements outlined in the
FDA Safety and Innovation Act (FDASIA) move towards
electronic submission of IND applications in Electronic
Common Technical Document (eCTD) format. We hope the
FDA will make special accommodations for academic sites
regarding PET probes in tracer doses by waiving the
requirement for submission of eCTD INDs or providing
additional tools to academic sites that reduce the cost and
time of IND submissions while still maintaining the quality
and safety standards relevant to PET probes.
It is critical for academic sites to have a streamlined and
cost-effective approach to translate PET imaging probes from
preclinical research to clinical investigations and investigate
the degree to which preclinical ﬁndings for these probes apply
to humans. This will allow for the (1) development and
introduction of new molecular imaging diagnostics of disease
that serve as an array of new assays to investigate the in vivo
biology of disease in patients, (2) aid in the drug discovery and
development processes, and (3) patient stratiﬁcation for
appropriate drug(s) and assessing therapeutic responses.
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